- Company
- Samsung BioLogics' sales surpassed ₩1 trillion
- by Chon, Seung-Hyun Oct 28, 2021 05:58am
- Samsung BioLogics surpassed 1 trillion won in sales in three quarters. Sales exceeded 1 trillion won in nine years after its establishment last year, and it showed a steeper rise this year. Samsung Biologics announced on the 26th that its operating profit as of the third quarter was 167.4 billion won, up 196.12% from a year earlier. Sales
- Company
- 'Vyndamax' fails reimbursement listing once again
- by Eo, Yun-Ho Oct 27, 2021 05:49am
- The new transthyretin amyloid cardiomyopathy (ATTR-CM) drug, 'Vyndamax,’ is suffering hardships in its process of being listed for insurance benefit. According to industry sources, the application Pfizer Korea submitted for the reimbursement of its new ATTR-CM drug, Vyndamax (tafamidis 61mg), was unable to pass the insurance benefit sta
- Company
- The supply of 8 GSK vaccines will be suspended until Feb
- by Oct 27, 2021 05:49am
- The supply of eight GSK vaccines, including Rotarix, is temporarily suspended, which is expected to disrupt the inoculation schedule. According to the pharmaceutical industry on the 26th, GSK announced a temporary suspension of supply of its vaccines to clinics and hospitals. Discontinued vaccines are ▲Rotarix (Human Rotavirus Live Att
- Company
- Celltrion's self-test kit has been approved for EUA
- by Chon, Seung-Hyun Oct 27, 2021 05:49am
- Celltrion announced on the 25th that the COVID-19 antigen rapid self-test kit DiaTrust COVID-19 Ag Home Test, jointly developed with Humasis recently acquired Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). Celltrion received the EUA of Celltrion DiaTrust™ COVID-19 Ag Rapid Test for Professionals from the FDA
- Company
- Sales of choline alfoscerate rise despite controversy
- by Chon, Seung-Hyun Oct 26, 2021 05:53am
- Sales of brain function enhancer ‘choline alfoscerate’ are on the rise in the prescription drug market. The drug recorded growth for 3 consecutive quarters despite controversy over its efficacy, reduced scope of reimbursement, and the restitution of insurance benefits. Also, with many CA products withdrawing from the market after giving up cl
- Company
- Merck will actively support Korea to become one of the top 5
- by Oct 26, 2021 05:53am
- M Lab has promised to actively invest and expand cooperation with domestic companies to expand its capabilities in Korean vaccine production and bio-process. In an online press conference hosted to commemorate the 5th anniversary of its establishment on the 21st, M Lab said, "We will support Korea to leap into one of the top five global vacc
- Company
- ‘Brilinta’ generic to be released next month
- by Kim, Jin-Gu Oct 25, 2021 05:50am
- Generics of AstraZeneca’s oral antiplatelet therapy Brilinta will be released next month. However, only 6 of the 25 companies that received first generic exclusivity will be releasing actual products. The small number of releases is interpreted to be caused by the domestic companies' declining interest in Brilintagenerics. According t
- Company
- Boryung Pharmaceutical acquired Zyprexa's domestic rights
- by Kim, Jin-Gu Oct 25, 2021 05:49am
- Boryung announced on the 21st that it has signed an asset transfer contract with Eli Lilly for the schizophrenia treatment "Zyprexa (Olanzapine)." Through this contract, Boryung will take over all rights from Eli Lilly, including domestic copyrights and permits for Zyprexa. Zyprexa is the world's most prescribed treatment for schizophreni
- Company
- Supreme court to finally rule on ‘Galvus’ patent dispute
- by Kim, Jin-Gu Oct 22, 2021 05:45am
- The 4-year long patent dispute over the patent of the anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ will finally come to an end at the Supreme Court on the 28th. Industry officials believe that the Supreme Court’s decision may affect and modify the overall patent strategies of generic companies in the coming future. If the Supreme
- Company
- COVID antibody kits are entering the market of clinics
- by Kim, Jin-Gu Oct 22, 2021 05:44am
- Although the sale of COVID-19 antibody diagnostic kits to pharmacies has been banned, diagnostic kit companies are speeding up into the market, especially in hospitals and clinics. It is explained that the industry's impact from the government's measures is not significant because it has focused on the hospital and clinic markets rather th
